Altered BAG3-insulin colocalization is associated with impaired first phase insulin secretion in humans
Authors' conclusion
BAG3 appears associated to first-phase insulin secretion in humans by influencing insulin granule exocytosis. Targeting BAG3 could represent a novel therapeutic approach to prevent or delay β-cell dysfunction and the onset of T2DM.
Study context
- Population
- Patients with no previous T2D diagnosis enrolled for partial pancreatectomy; pancreatic tissue samples
- Participants
- 12 patients
- Comparison
- HIGH vs LOW BAG3-insulin colocalization in human islets
- Outcome
- First-phase insulin secretion
Main finding
As reported in the abstract
- HIGH BAG3: significantly impaired first-phase insulin secretion, with reduced rate sensitivity during OGTT
- HIGH BAG3: higher plasma glucose at 30 and 60 min post-glucose challenge
- HIGH BAG3: increased islet size; no differences in insulin/glucagon ratios or insulin sensitivity
Original publication
Altered BAG3-insulin colocalization is associated with impaired first phase insulin secretion in humans. Diabetes Res Clin Pract. Published 7 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →